Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894946 | 1.00 | SLC9A1 (0.50) | SLC9A1SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL12894947 | 1.00 | SLC9A1 (0.50) | SLC9A1SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL799768 | 0.86 | ALDH1A1 (0.54) | SLC6A4SLC6A3ALDH1A1LMNATP53 | |
| SCHEMBL451958 | 0.84 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15314508 | 0.84 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL440565 | 0.84 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL13859341 | 0.84 | SLC9A1 (0.50) | SLC9A1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15977398 | 0.84 | MAPK1 (0.55) | SLC9A1ALDH1A1HPGD | |
| SCHEMBL15977397 | 0.84 | MAPK1 (0.55) | SLC9A1ALDH1A1HPGD | |
| SCHEMBL15977388 | 0.84 | MAPK1 (0.55) | SLC9A1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268140-B1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | HRH3, HRH4, HRH1 | SLC9A1 320/4885SLC6A4 466/4885SLC6A3 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.